Want to see AU:PKY full AI Analyst Report?
PKY Stock Chart & Stats
AU$0.03
--
Market closed
AU$0.03
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.13M
Market Cap
AU$59.01M
Enterprise ValueAU$21.31M
Total Cash (Recent Filing)AU$580.84K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,204,316,000
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-driven Drug DiscoveryOpyl's core focus on AI and data-driven drug discovery aligns with a durable structural tailwind in pharma R&D. Computational approaches can meaningfully shorten development cycles and create scalable, repeatable workflows that appeal to long-term pharmaceutical customers.
Pharma & Biotech Customer FocusSelling services and tools to pharmaceutical and biotech firms targets a high-value, long-duration buyer base. When product-market fit is achieved, these relationships can yield multi-year engagements and recurring workflows, supporting sustainable revenue once commercial traction returns.
Lean Operating FootprintA very small headcount implies low fixed overhead and the ability to extend runway versus larger peers. This lean structure supports capital efficiency, enables iterative R&D with outsourced execution, and allows management to reallocate limited resources toward core product development.
Bears Say
Severe Revenue DeclineAn ~86% year‑over‑year revenue collapse is a structural red flag: it suggests loss of customer demand or product-market fit and materially weakens the firm's ability to demonstrate scalable, repeatable sales. Sustained top-line contraction impairs reinvestment and long-term growth prospects.
Persistent Unprofitability And Negative MarginsConsistent negative gross and operating margins indicate a fundamental mismatch between revenue and cost structure. This prevents self-funding, necessitates ongoing external capital, restricts R&D investment, and raises execution risk for any long-term scaling strategy.
Negative Equity And Rising DebtNegative shareholders' equity and increasing debt produce a fragile capital structure, reducing financial flexibility and increasing funding risk. Higher leverage and impaired equity cushion constrain strategic options and raise the likelihood of dilution or costly financing to sustain operations.
Opyl Ltd. News
PKY FAQ
What was Opyl Ltd.’s price range in the past 12 months?
Opyl Ltd. lowest share price was AU$0.01 and its highest was AU$0.07 in the past 12 months.
What is Opyl Ltd.’s market cap?
Opyl Ltd.’s market cap is AU$59.01M.
When is Opyl Ltd.’s upcoming earnings report date?
Opyl Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 47 days.
How were Opyl Ltd.’s earnings last quarter?
Opyl Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Opyl Ltd. overvalued?
According to Wall Street analysts Opyl Ltd.’s price is currently Overvalued.
Does Opyl Ltd. pay dividends?
Opyl Ltd. does not currently pay dividends.
What is Opyl Ltd.’s EPS estimate?
Opyl Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Opyl Ltd. have?
Opyl Ltd. has 1,204,316,000 shares outstanding.
What happened to Opyl Ltd.’s price movement after its last earnings report?
Opyl Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Opyl Ltd.?
Currently, no hedge funds are holding shares in AU:PKY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opyl Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PKY Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.74%
12-Months-Change
Fundamentals
Return on Equity
-1122.02%
Trailing 12-Months
Asset Growth
129.09%
Trailing 12-Months
Company Description
Opyl Ltd.
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven solutions: TrialKey, a sophisticated platform for simulating and optimizing trial designs to boost success rates, and TrialGen, an AI-powered utility crafted to simplify the clinical trial design process. They extend their services to a diverse clientele, encompassing biopharmaceutical companies, MedTech innovators, governmental agencies, and various healthcare organizations. Established in Sydney in 1994, the entity known today as Pathkey.AI Ltd will formally change its name from Opyl Limited in August 2025.
Technical Analysis
Cogstate Ltd
―
Oneview Healthcare Chess Depository Interests repr 1
―
Beamtree Holdings Ltd
―
MedAdvisor Limited
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---